Metsera, Inc. (MTSR) has received a new Buy rating, initiated by Bank of America Securities analyst, Tim Anderson.
Tim Anderson has given his Buy rating due to a combination of factors including Metsera, Inc.’s innovative approach in the obesity market, which is projected to reach approximately $170 billion by 2030. The company stands out with its multi-asset and platform offerings, including both oral and injectable solutions, and currently has three assets in human studies. The management team’s relevant experience and the presence of five significant catalysts over the next year further strengthen its position.
Metsera’s lead assets, MET-097i and MET-233i, are novel injectables with long half-lives, offering unique attributes such as no need for dose changes during initial titration and convenient monthly dosing during maintenance. These differentiating factors are crucial for new entrants in the obesity sector. Additionally, Metsera’s oral peptide platform shows promise with potentially higher bioavailability compared to existing solutions. With sufficient cash reserves to last through 2026 and several key clinical readouts expected in 2025, Metsera is well-positioned for future growth, justifying the Buy rating.
In another report released today, Guggenheim also initiated coverage with a Buy rating on the stock with a $56.00 price target.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MTSR in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com